L3VLUP
ProSign in

GKOS · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

GKOSVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • GKOS
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterGKOSVRTX
Q3 20207 holders, $495m31 holders, $21.9bn
Q4 20206 holders, $742m30 holders, $18.4bn
Q1 20218 holders, $1.1bn31 holders, $15.4bn
Q2 20217 holders, $857m30 holders, $12.7bn
Q3 202111 holders, $539m35 holders, $10.1bn
Q4 202111 holders, $452m28 holders, $12.4bn
Q1 20228 holders, $622m23 holders, $16.1bn
Q2 20228 holders, $497m25 holders, $18.1bn
Q3 202211 holders, $492m22 holders, $18.4bn
Q4 20229 holders, $435m28 holders, $18.4bn
Q1 20239 holders, $510m26 holders, $21.4bn
Q2 20238 holders, $729m27 holders, $24.7bn
Q3 20237 holders, $551m33 holders, $24.3bn
Q4 20239 holders, $768m32 holders, $28.6bn
Q1 20246 holders, $1.1bn31 holders, $29.8bn
Q2 20247 holders, $1.4bn29 holders, $33.4bn
Q3 20247 holders, $1.5bn27 holders, $33.5bn
Q4 202410 holders, $1.9bn26 holders, $28.5bn
Q1 202510 holders, $1.3bn21 holders, $35.4bn
Q2 202510 holders, $1.6bn21 holders, $32.3bn
Q3 20259 holders, $736m22 holders, $25.9bn
Q4 20257 holders, $1.0bn26 holders, $31.8bn
Q1 20268 holders, $1.2bn25 holders, $31.8bn
Q2 20269 holders, $1.5bn26 holders, $34.6bn
GKOS

Glaukos Corp

Holders
10
Reported value
$1.6bn
Buyers
6
Sellers
3

Breadth +3 among 95 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
VRTX

Vertex Pharmaceuticals Inc

Holders
21
Reported value
$32.3bn
Buyers
11
Sellers
11

Breadth 0 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2025

Among the 25 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only GKOS (4)

Farallon Capital Management LLC, Freestone Grove Partners LP, Holocene Advisors LP, Point72 Asset Management LP

Only VRTX (15)

AQR Capital Management LLC, ARK Investment Management LLC, Baillie Gifford & Co, Bridgewater Associates LP, Capital Research Global Investors, Hudson Bay Capital Management LP, Invesco Ltd, Man Group PLC, Marshall Wace LLP, MFS Investment Management, Neuberger Berman Group LLC, Renaissance Technologies LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →